Posted in Regulatory AZ considers filings for long-acting Strensiq follow-up March 31, 2026 Pharmaphorum AstraZeneca’s long-acting Strensiq follow-up efzimfotase alfa has hit the mark in children with rare disease HPP, but the data in adults is unclear. RegulatoryRare DiseaseRead full story